QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Pregnancy Prevention Programmes in the EU

Test your understanding of the concepts covered by GVP Module XVI: Pregnancy Prevention Programmes in the EU — Risk Minimisation and Member State Implementation.

Question 1 of 10Pass mark: 80%

Question 1 of 10 If a critical dispensing control fails because required documentation is missing, what should a well-designed PPP provide?

A process that allows dispensing to continue without recording the failure A predefined, clinically appropriate response consistent with product information and national requirements Automatic permanent withdrawal of treatment for every patient No response because documentation has no role in risk minimisation

Question 2 of 10 Which situation most clearly calls for controlled change management within a PPP?

A change to the testing interval or dispensing workflow that could alter when a critical safety decision is made A routine reprint with no change to content, version or distribution process An unrelated change to the company’s office location A decision to stop collecting all effectiveness data

Question 3 of 10 Why does the presence of an embryo-fetal or teratogenic risk not automatically require a full PPP?

Because embryo-fetal risks are addressed only through routine pharmacovigilance Because a PPP is selected proportionately, taking account of the risk, indication, population, duration and existing controls Because PPPs are permitted only for centrally authorised medicines Because pregnancy testing can never be used as an additional risk-minimisation measure

Question 4 of 10 What lesson does the comparison of France, Austria and Spain primarily illustrate?

Member States must use identical PPP documents and prescriber categories National procedural differences necessarily represent different safety objectives A common embryo-fetal risk objective can be implemented through different national control architectures Only France has a structured PPP for retinoid medicines

Question 5 of 10 Which statement best distinguishes EU-level requirements from national implementation?

National workflows can replace an EU-level requirement whenever they are more convenient All national operational details are automatically EU legal requirements The safety objective may be common while national systems determine the practical prescribing, testing, documentation and dispensing workflow EU-level requirements apply only where a country uses electronic prescribing

Question 6 of 10 A national authority requires specialist initiation of treatment for a product, but the applicable EU materials do not specify specialist prescribing. How should this be described?

As an EU-wide PPP requirement in all Member States As a national implementation control unless the applicable EU regulatory text establishes it more broadly As evidence that the EU risk-minimisation objective is different in that country As an optional suggestion with no relevance to implementation

Question 7 of 10 Why can a pregnancy test performed too early be an inadequate control even if the result is negative?

A negative result is never clinically useful in a PPP The result may no longer provide sufficient assurance at the time treatment is prescribed or dispensed Testing is relevant only after the final dose The test becomes invalid whenever contraception is used

Question 8 of 10 What is the most appropriate QPPV response when national implementation differs from the EU-level PPP concept?

Ignore the difference because national practice is outside pharmacovigilance governance Require identical national workflows regardless of healthcare-system context Document the difference, assess consistency with the agreed RMM, and evaluate whether it creates a safety or effectiveness concern Replace the EU-level RMM with the most restrictive national process

Question 9 of 10 Which sequence best represents the control logic of a PPP?

Distribute materials, close the programme, then review outcomes if reported Identify the risk, define the objective, specify controls, document operation and evaluate effectiveness Restrict all prescribing first, then determine whether the product presents a pregnancy risk Collect pregnancy outcomes first, then decide whether any controls are needed

Question 10 of 10 A product is generally contraindicated during pregnancy but has an exception where no suitable alternative exists. What should the PPP do?

Convert the general precaution into an absolute prohibition in all circumstances Remove all pregnancy-prevention controls because an exception exists Make the eligibility condition and the clinical exception explicit so that the decision pathway is preserved Allow treatment whenever the patient signs an acknowledgement form

Knowledge Assessment: Pregnancy Prevention Programmes in the EU

Cookie Settings